Handok Appoints Kim Mi-yeon as New CEO

Handok announced on the 28th that it will appoint Kim Mi-yeon as the new president effective from the 1st of next month.

Kim, who holds a bachelor's degree in English Language and Literature from Yonsei University, a master's degree in Communication from the University of Michigan, USA, and completed an MBA program at Yale University, served as a strategic planning manager, brand manager, and marketing manager at Pfizer Korea before overseeing the Established Product (EP) business division. She later managed all brands in the U.S. as Vice President of the EP division at Pfizer's headquarters in the United States. She also served as head of cardiovascular and metabolic disease business at Novartis Korea and as CEO of Alcon Korea. Recently, she led the mid- to long-term management strategy and strengthened sustainable management as CEO of Genewon Science, the integrated corporation of Kolmar Pharma and Kolmar Pharmaceutical Business Division.

Handok described President Kim as a healthcare leader who has achieved remarkable results in the pharmaceutical and medical device industries, possessing diverse experience in management and strategic planning, brand marketing, drug pricing and reimbursement, organizational management, and customer experience. She is also recognized for her outstanding ability to analyze the rapidly changing healthcare market, establish management strategies and execution plans, and create results through collaborative leadership by cooperating with various stakeholders.

Kim Young-jin, Chairman of Handok, said, “We are very pleased to have Kim Mi-yeon, who has excellent expertise and leadership in the healthcare field, join us,” adding, “She will play a crucial role in helping Handok establish differentiated competitiveness and grow in the rapidly changing healthcare market.”

This content was produced with the assistance of AI translation services.